Drugs / Ralmitaront
Ralmitaront
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06880328 | Nov 2018 → Sep 2019 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02699372 | Mar 2016 → Apr 2017 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04512066 | Sep 2020 → Jun 2022 | schizoaffective disorder, schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT03669640 | Dec 2018 → Mar 2023 | schizoaffective disorder, schizophrenia | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ralmitaront | “A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder” NCT04512066 ↗ |
| Known as | RG-7906 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594376 ↗ |
| Known as | RO6889450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04512066 ↗ |
| Modality | Small molecule | — CHEMBL4594376 ↗ |
| Route | Oral | “receive single oral dose of RO6889450” NCT02699372 ↗ |